At GoBroad, we are not just a hospital—we are a cancer research hospital dedicated to revolutionizing cancer treatment. Our mission extends beyond conventional care; we focus on groundbreaking clinical research and innovative therapies that reshape the future of oncology.

Recently, we achieved a significant milestone by obtaining approval for the clinical application of Lutetium-177 (Lu-177), a radiopharmaceutical therapy that brings new hope to patients with neuroendocrine tumors. This marks a crucial step forward in nuclear medicine, reinforcing our commitment to leading-edge cancer treatment.

Leading the Way in Nuclear Medicine

Since a long time ago, China has maintained strong rules on nuclear medicine, which has resulted in approvals being difficult to obtain and highly selective. The fact that we were able to obtain approval for Lu-177 therapy is evidence of both our competence and our commitment to becoming a pioneer in the field of advanced medicines.

We are now conducting clinical trials for Peptide Receptor Radionuclide Therapy (PRRT), which has been demonstrated to provide greater control over neuroendocrine tumors in comparison to other medicines that are currently available. These trials are being led by the esteemed professor Lu Ming from Peking University Cancer Hospital and GoBroad. With a positive attitude, we continue to investigate and put into practice the revolutionary potential of nuclear medicine in order to guarantee that our patients receive care of the highest possible standard.

A Research-Driven Approach to Cancer Treatment

We, as a hospital that specializes in cancer research, recognize the importance of scientific discovery and innovation as basic cornerstones of our profession. In order to create and translate innovative medicines from the research stage to the clinical application stage, we work together with the most prestigious medical institutes.

Precision medicine and focused treatments that improve survival rates and enhance quality of life are the primary focuses of our approach, which is oriented on the patient first and foremost. We ensure that every patient receives the benefits of medicines that are not only effective but also suited to their particular medical needs by incorporating the most recent breakthroughs in biotechnology.

Conclusion

At GoBroad, our dedication to advancing cancer research and clinical innovation remains unwavering. As we continue to push the boundaries of medical science, we reaffirm our commitment to being a leading cancer research hospital that transforms lives. With every breakthrough, we bring renewed hope to patients and their families, paving the way for a future where cancer is no longer a life-threatening disease.